news
SARS-CoV-2 antibodies can bind to two viral targets at once
US researchers find that SARS-CoV-2 bivalent antibodies can continue to neutralise Omicron and Omicron lineages.
List view / Grid view
La Jolla Institute for Immunology (LJI)
news
“Slow” vaccine delivery improves immune response to HIV
An experimental HIV vaccine, delivered as increasing doses over several days, led to long-lasting and diverse antibody production in monkeys.
news
Genetic study could influence the development of COVID-19 therapies
The study is the first in-depth look at links between COVID-19 severity and gene expression in immune cells and may guide future therapies.
news
$2.6 million granted to create pan-coronavirus vaccine
The La Jolla Institute for Immunology and Brigham and Women's Hospital will collaborate to develop a pan-coronavirus vaccine.
news
T-cell exhaustion may limit long-term immunity in COVID-19 patients
Researchers suggest patients who develop mild COVID-19 may not be able to fight reinfection very effectively because their CD8+ T cells show signs of exhaustion.
news
Researchers emphasise importance of antigen valency for vaccine efficacy
Researchers have shown that factoring in valency to vaccine design can improve the number of antibody binding sites on an antigen.
news
Researchers halt type 1 diabetes onset by denervating the pancreas
Scientists denervated the pancreas using surgery or pharmacological agents to protect it from immune-mediated beta cell destruction, preventing the onset of type 1 diabetes.
news
Potential target to control T follicular helper cells identified
A new study shows how the Bcl6 protein can regulate T follicular helper cells, presenting a target for autoimmune and infectious diseases.